tirzepatide surpass cvot A comparison of the effects of and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial Inside SURPASS-CVOT With Dr. Stephen

For research collaborations or media inquiries related to real-world GLP-1 outcomes, please contact: [email protected]

The evaluation process is thorough despite being virtuallegitimate telehealth providers require complete health histories, review contraindications carefully, and maintain ongoing oversight throughout treatment

Key outcomes included major adverse cardiovascular events (MACE), venous thromboembolism (VTE), kidney disease progression, and all-cause mortality, an outcome spectrum highly relevant to patients with SLE and T2D

Our team has been tracking these conversations closely, and it's time to unpack what we know, what we don't, and what the research community should be watching for